A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer – Beyond the Abstract
prostate cancer, advanced prostate cancer, androgen deprivation therapy (ADT), Relugolix, Dosing of Relugolix, gonadotropin-releasing hormone (GnRH) receptor antagonist, HERO study, abiraterone acetate, apalutamide, metastatic castration-sensitive prostate cancer (mCSPC).